Across TCGA pan-cancer cohorts, POTEJ mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated POTEJ data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher POTEJ mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated POTEJ expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where POTEJ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.533	0.849	.006	22	view →
PDAC	DFS	Tertile	IV	0.190	0.546	.038	3	view →
CCRCC	DFS	Median	IV	0.749	0.253	.044	2	view →
HNSC	DFS	Quartile	III,IV	0.929	0.721	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: POTEJ tumor-vs-normal RNA expression · all POTEJ data types